



UvA-DARE (Digital Academic Repository)

Discharging dopamine

Boosting endogenous tyrosine hydroxylase activity as a treatment for Parkinson's disease

Stoop, J.

Publication date

2023

[Link to publication](#)

Citation for published version (APA):

Stoop, J. (2023). *Discharging dopamine: Boosting endogenous tyrosine hydroxylase activity as a treatment for Parkinson's disease*. [Thesis, externally prepared, Universiteit van Amsterdam].

General rights

It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: <https://uba.uva.nl/en/contact>, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

GENERAL INTRODUCTION

Targeting tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis as a treatment for Parkinson's disease

J. Stoop¹


V. I. Wiersma^{1,2}

M. P. Smidt¹

L. P. van der Heide¹

¹ Swammerdam Institute for Life Sciences, University of Amsterdam,
Science Park 904, 1098XH, Amsterdam, the Netherlands

² Current address: Department of Quantitative Biomedicine,
University of Zurich, Winterthurerstrasse 190, 8057, Zurich,
Switzerland



Parkinson's disease

Parkinson's disease (PD) is the second most prevalent neurodegenerative disease worldwide ¹ that affects 1-2 individuals per 1000 humans of the population in Europe ². The prevalence of PD increases with age to 1% of patients that are above 60 years old ^{3,4}. The symptoms are caused by progressive degeneration of dopaminergic neurons in the Substantia Nigra pars compacta (SNpc), located in the midbrain ⁵. Human SNpc neurons contain the dark pigment neuromelanin, and loss of SNpc neurons, marked by depigmentation in PD patients is clearly visible at neuropathological examination ⁶ (Fig. 1, upper section). SNpc dopamine neurons project to the corpus striatum ^{7,8}, one of the forebrain centers in charge of motor control (Fig. 1, upper section). The functional connectivity between both structures is referred as the nigrostriatal pathway and depends on the release of the catecholamine dopamine ⁹. Due to the neuronal degeneration in the SNpc, there is less projection of dopaminergic fibers from the SNpc to the striatum (Fig. 1, lower section), resulting in a decreased dopamine release.




Figure 1. Nigrostriatal degeneration of dopaminergic neurons

Illustration of the functional connectivity between the SNpc in the midbrain (cell bodies) and the striatum (terminals) that is called the nigrostriatal pathway. Additionally, the mesolimbic pathway, the connectivity between the VTA that projects towards the ventral striatum/NAc and prefrontal cortex is illustrated. Both pathways depend on the release of dopamine and are known to be involved in PD pathology. Coronal midbrain section of normal healthy versus PD state of the SNpc (dark gray). Loss of pigmentation of neuromelanin in PD patients is clearly visible, in which approximately 70% of SNpc neurons already have been lost. Degeneration of nigrostriatal and mesolimbic dopaminergic neurons in the midbrain causes a reduction in the amount of dopamine neurons, functional dopamine neuron terminals and dopamine transmission. *Abbreviations: NAc, Nucleus Accumbens; PD, Parkinson's disease; SNpc, Substantia nigra pars compacta; VTA, Ventral Tegmental Area.*

Studies reported that additionally but to a lesser extent the connectivity from the ventral tegmental area (VTA) to the ventral striatum, called the mesolimbic pathway is affected as well ¹⁰. To date there is no cure to halt the observed neurodegeneration.

When patients are diagnosed, PD is characterized by a range of motor symptoms, such as bradykinesia, akinesia, muscle cramps and tremor at rest ^{11–13}. PD is also featured by a variety of non-motor symptoms, such as cognitive dysfunction, depression, anxiety, delusion, sleep abnormalities, hallucination, and impulsive and compulsive behaviors ^{14,15}, suggestively partly influenced by given therapy. Strikingly, clinical symptoms only emerge at an advanced disease stage, in which a substantial amount of approximately 70% of SNpc neurons has already been lost and its numbers are still declining ¹⁶. Before clinical diagnosis and obvious PD-like motor symptoms, the patients go through a so-called prodromal phase ¹⁷. Prodromal PD symptoms include loss of smell, constipation, mood disruptions, and problems sleeping ^{17,18}. Interestingly, the prodromal symptoms can occur as early as 20 years before the onset of motor symptoms ¹⁹. Thus, improving diagnosis would be beneficial to start treatment as early as possible that could delay the onset of clinical symptoms and improve the patient's quality of life.

Only around 10% of PD cases have a monogenetic cause, and the remaining 90% of cases are sporadic, where the chance of developing PD increases with age ²⁰. Several mutations in genes, such as glucocerebrosidase (*GBA*), leucine-rich repeat kinase 2 (*LRRK2*), Parkin (*PARK2*), UCHL1 (*PARK5*), DJ-1 (*PARK7*), PTEN-induce putative kinase 1 (*PINK1*), α -synuclein (*SNCA*), vacuolar protein sorting-associated protein 35 (*VPS35*) and other genes have been associated with increased risk for PD ^{21–26}. Environmental factors such as toxins, pesticides, intake of heavy metals, dairy products and head trauma are all found to increase PD risk ^{27–34}.

Treatment opportunities

L-DOPA: the current therapy for Parkinson's disease

Dopamine in dopaminergic midbrain neurons is synthesized by the enzyme Aromatic amino acid decarboxylase (AADC) from the precursor L-3,4-dihydroxyphenylalanine (L-DOPA). Prior, L-DOPA is synthesized by tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine synthesis (Fig. 2A).

To replenish the decreased level of dopamine, and as soon as a PD patient exhibits motor symptoms, they are treated orally with L-DOPA, which is considered the gold standard in the treatment of PD. L-DOPA is administered together with the AADC inhibitor carbidopa, that does not pass the blood brain barrier (BBB) to prevent peripheral conversion of L-DOPA to dopamine ^{35–38}. Absorption of L-DOPA takes place in the small intestine, through the L- amino acid transport (LAT) system, sharing uptake with other essential large amino acids ³⁹. Only 30% of the oral L-DOPA supplementation reaches the circulation intact ³⁹ of which merely 1% enters the brain ^{39,40}. L-DOPA is effective at plasma concentrations of 2 $\mu\text{g}/\text{mL}$ ³⁹, however effectiveness is unpredictable when disease state progresses ⁴¹.

From the circulation, L-DOPA reaches the brain via cerebral arteries, passes the BBB via active transport via LAT, and is dispersed all over the brain ^{42–46}. After an initial period of 5-10 years of effective levodopa treatment (honeymoon period), patients develop fluctuations in

their therapeutic response, leading to a 'wearing-off' effect, in which the therapeutic effect is shortened in duration of each consecutive L-DOPA dosage^{47–49}. Accordingly, L-DOPA treatment requires regular incremental adjustments in dosage and dosages per day. Interestingly, it is suggested that the presence of L-DOPA reduces the uptake of L-Tyrosine^{50–52}. This possibly further downscales the endogenous dopamine production and elevates the dependence of exogenous L-DOPA delivery.

The production of dopamine from L-DOPA by the enzyme AADC, is however not restricted to dopamine neurons in the midbrain, but it also facilitates additional enzymatic reactions in other neuronal cell type systems. These AADC-positive systems include the brain serotonin system, the noradrenergic system, trace amine neuromodulator systems, and glial cells^{45,53–55} (Fig. 2B). The expression of AADC in serotonin neurons is suggested to underlie one of the major side-effects observed after long-term levodopa treatment: Levodopa-induced-dyskinesia (LID). LIDs are suggested to be the result of AADC-mediated biosynthesis of dopamine that is derived from exogenous L-DOPA in serotonergic neurons^{56,57}. These afferent nerves will additionally serve a role for storage and release of L-DOPA-derived dopamine⁵⁸. Therefore, dopamine will be released from non-dopaminergic afferents, resulting in uncontrolled, excessive swings in dopamine release. Serotonin transporter blockade with selective serotonin reuptake inhibitors (SSRIs) was recently shown to counteract L-DOPA-induced dyskinesias in 6-hydroxydopamine (6-OHDA)-lesioned rats^{59–62}. Also, lesions of the serotonin fibers or activating serotonergic auto-receptors with receptor agonists blocked the development of LID in lesioned animals^{63–66}.

Post-synaptic targeting: Medium Spiny Neurons

To completely bypass presynaptic dopamine synthesis, Dopamine receptor agonists already are implemented as a therapy for PD^{67–69}. Dopamine receptors in the post-synaptic membrane of medium spiny neurons (MSNs) are targeted to enhance the neuronal signaling action potential, increasing its sensitivity. Results demonstrate improved mobility and a prolonged motor response mediated by L-DOPA in PD patients, suggesting a long-lasting effect of treatment. However, their complicated mode of action is proposed controversial, with lower efficacy and high incidence of adverse effects^{70–73}. One of the issues is that these agonists are not specific, because of the wide distribution of dopamine receptors within different brain regions^{74–77}.

Recently, several gene therapy methods for PD went into clinical trials^{78–80}. Some methods that are included are AADC-TH-GCH gene therapy, viral vector-mediated gene delivery, RNA interference-based therapy, and CRISPR-Cas9 gene editing^{80,81}. In AADC-TH-GCH gene therapy, AADC, TH and glutamic acid decarboxylase (GCH), enzymes that are crucial in dopamine biosynthesis are used⁸². The MSNs, that are not affected in PD are targeted to synthesize dopamine and showed improved motor performance and sustained expression of the genes in phase 1 human trials and primates^{83–88}. They found that gene delivery indeed resulted in increased levels of dopamine^{89,90}. Nevertheless, it has been debated whether MSNs are the right target at all because they lack the ability to store and release dopamine properly⁷⁸, leading to unregulated expression levels that can lead to harmful levels of dopamine and its metabolites^{91–93}.




Figure 2. Biosynthesis of dopamine

The biosynthetic pathway of dopamine. **A** | TH has a predominant role in the biosynthesis pathway of dopamine. TH uses oxygen (O₂), the cofactor Tetrahydrobiopterin (BH₄), and a ferrous iron (Fe²⁺) atom in the active site to facilitate the catalytic reaction of L-tyrosine to L-3,4-dihydroxyphenylalanine (L-DOPA). In turn, aromatic amino acid decarboxylase (AADC) decarboxylates L-DOPA to dopamine. **B** | Illustration describing the dopamine supplementation therapy by L-DOPA for PD patients. L-DOPA, which can pass the blood-brain barrier, is usually administered peripherally in combination with a peripheral AADC inhibitor. It reaches the brain via cerebral arteries and passage of the blood-brain barrier. Then, through activity of AADC, L-DOPA is converted to dopamine in the brain. The presence of AADC is, however, not limited to dopamine-synthesizing neurons. Accordingly, in addition to the original treatment target area, L-DOPA reaches various AADC-containing neuronal cell types in diverse brain regions. Consequently, dopamine is synthesized in AADC-containing neurons that normally synthesize neurotransmitters or modulators other than dopamine, for example serotonin neurons in the raphe nuclei.

Replacement therapies: Cell reprogramming and transplantation

For almost half a century cell transplantation therapies have been researched to commemorate the loss of dopamine neurons and catecholamine signaling in PD. However, efficacy was dramatically low and severe side effects occurred, also in later studies^{94–96}. Gladly, clinical cell therapy for PD has been picked up again for the last decades. Cells that are mainly used as a therapy are human embryonic stem cells (hESCs), human induced pluripotent stem (iPS) cells, and human fetal mesencephalic tissue^{97,98}. hESCs have some beneficial properties such as unlimited self-renewal capacity and potential to differentiate into specialized cells⁹⁹. Kriks *and other researchers* described successful conversion of hESCs to dopaminergic neurons, showing long survival, no tumor growth and an increase in dopamine production^{100–104}. Allografts of human fetal ventral mesencephalic (VM) tissue is currently suggested to be the most effective cell replacement therapy for PD patients. These allografts contain developing midbrain dopamine neurons and their precursors¹⁰⁵. Some successful open-lab trials that exist in this area reported improved motor symptoms in a selection of PD patients^{8,106,107}. In the last decade, induced pluripotent stem cells (iPSCs), are also used for reprogramming into dopamine cells^{108,109}. Hallett *and colleagues* reported that iPSC reprogrammed dopaminergic neurons, transmitted into the striatum of a monkey PD model, showed survival of transplanted

neurons and motor progression ¹¹⁰. The benefits of using this iPSC model are that patient-specific cells can be acquired, which reduces immune reactions and ethical issues associated compared to other transplantation therapies ^{111–113}. However, these techniques still comprise of a great deal of challenges. Apart from the obvious complexity of the procedure, problems that occur such as the purity of the material injected, the risk of tumorigenesis, immune reactions, ethical issues, pathology and a variety of other challenges should first be resolved ^{97,114}.

Halting neurodegeneration: Blocking mitochondria-dependent apoptosis

Halting or slowing down the progressive degeneration of dopaminergic neurons in the Substantia pars compacta (SNpc) would be a breakthrough in the treatment of PD. First, the molecular mechanism underlying dopaminergic cell death in PD should be elucidated, exposing the intrinsic vulnerability of these neurons. Promising results in pre-clinical cell and animal PD models demonstrated degrees of neuroprotection, however clinical attempts to achieve neuroprotection have been disappointing ^{115–117}. Interestingly, in PD pathology, accumulating evidence aims towards mitochondria-dependent apoptosis underlying neuronal loss ^{118,119}. Blocking mitochondria-dependent apoptosis may therefore be a therapeutic to prevent the loss of dopamine neurons ¹¹⁹. However, the components of the apoptotic pathway have to be identified first in midbrain dopamine neurons. To ensure proper development and maintenance of the dopaminergic system, it has been hypothesized that a set of transcription and growth factors orchestrate specific dopaminergic pro- and anti-apoptotic factors that determine cell fate ¹¹⁹. Nevertheless, early detection of PD pathology is necessary to prevent further loss of midbrain dopamine neurons for these therapeutics to be effective.

Proposed treatment

TH: the rate-limiting enzyme in dopamine biosynthesis

As previously discussed, TH is the rate-limiting step in dopamine biosynthesis. TH is a member of the Aromatic amino acid hydroxylases (AAAHs), that are involved in the biosynthesis and signaling of monoamine neurotransmitters and hormones. Other members of AAAH enzymes are phenylalanine hydroxylase (PAH) and tryptophan hydroxylase 1 and 2 (TPH1, TPH2). They catalyze the hydroxylation of their respective amino acids. AAAH enzymes require the co-factors tetrahydrobiopterin (BH4), oxygen and iron for this reaction to occur ^{37,120,121}. AAAHs are conserved tetrameric structures with identical subunits, however PAH can also exist as a dimer ^{37,122,123}. The subunits consist of a 3-domain organization including the N-terminal regulatory domain, central catalytic domain and C-terminal oligomerization domain ^{124–126} (Fig. 3A). The AAAHs display high-sequence identity, with 293 amino acid residues of catalytic domains, that demonstrate approximately 65% sequence identity across the sequence. AAAH's are therapeutic targets for many diseases within neurology, psychiatry and cardiology ¹²⁷. An example of this is the recessive disease phenylketonuria (PKU), associated with mutations in *PAH*, leading to loss of enzyme activity. Symptoms that arise are progressive intellectual impairment, autism, seizures, motor deficits and rash ¹²⁸. It is characterized by the accumulation of phenylalanine and its degradation products, which is very toxic to the brain. Treatment options are administration of large neutral amino acids to prevent phenylalanine entry into the brain or oral BH4 co-factor application to increase PAH activity ¹²⁹. Oral BH4 treatment is used for several disorders, such as hypercholesterolemia, diabetes mellitus, and cardiovascular disorders ^{130–136}. However, this is not considered for PD ^{137–139}. Another disease regarding

TH, called Tyrosine hydroxylase Deficiency (THD) is characterized by L-DOPA-responsive dystonia and/or infantile parkinsonism¹⁴⁰. This rare autosomal recessive disorder is largely caused by *TH* missense mutations and treated with L-DOPA supplementation^{140,141}.

Regulation of TH expression and enzyme activity

TH is present in the brain, retina, sympathetic nervous system, gut and adrenal medulla¹⁴², and predominantly found in the cytoplasm¹⁴³. In all species, *TH* is coded by a single gene and in human, *TH* is found on locus *11p15.5*. TH has a molecular weight of approximately 60 kDa and forms a functional homotetramer of 240 kDa. Interestingly, the human *TH* gene contains 14 exons that encode four isoforms of TH, hTH1, hTH2, hTH3 and hTH4, as a result of alternative splicing of the gene¹⁴⁴. The roles of the different isoforms in TH regulation are unclear. The TH protein found in other vertebrates is comparable to the human TH isoform hTH1. Isoforms hTH2, hTH3 and hTH4 have an additional 4, 27 or 31 (27+4) amino acids inserted on the N-terminus^{145,146}. In the caudate and putamen, hTH1 and hTH2 are expressed equally and account for 95% of the TH protein present¹⁴⁷.

In the adrenal medulla and locus coeruleus, stress or chronic drug treatments induced *TH* gene transcription and increased mRNA stability^{148,149}, indicating that TH is being regulated on the transcriptional level. However, in midbrain neurons, only modest or insignificant alterations in *TH* mRNA levels are observed during stressful events^{150–153}. In addition, more than 50 single nucleotide polymorphisms (SNPs) in the human *TH* gene have been described that occur in 1/3 of the population^{154–156}. These SNPs have been associated with a variety of uncommon movement disorders, such as L-DOPA-responsive dystonia, Parkinsonism and progressive infantile encephalopathy with L-DOPA-nonresponsive dystonia^{157–163}.

Besides regulation of TH via transcription¹⁶⁴, it can also be regulated via post-translational modifications such as phosphorylation and dephosphorylation, leading to changes in enzyme stability and feedback inhibition^{165–171}. The regulatory domain of TH harbors several conserved phosphorylation sites that are important for the regulation of its enzymatic activity. Conserved over species, the regulatory domain contains three serine residues (position 19, 31 and 40 in hTH1; Fig. 3B) that can be phosphorylated^{142,172–175}. It has been suggested that Ser8 in rodents and threonine 8 in human (Thr8) may be phosphorylated as well^{145,174,176}, however the function is never shown.

TH serine phosphorylation by a variety of protein kinases

Serine phosphorylation of TH harbors several functions. TH Ser40 phosphorylation augments enzymatic activity by altering the conformation of TH, leading to an increased dissociation of inhibitory catechols and increasing the affinity for its cofactor BH4^{142,170,175,177,178}. TH Ser31 phosphorylation promotes activity as well, although to a considerably lower extent than Ser40 and is involved in enzyme stability and localization^{173,179–184}. Ser19 phosphorylation is involved in enzyme stability and there is little evidence that Ser19 phosphorylation has a direct effect on TH activity^{181,185–190}. There is no evidence that Ser8 phosphorylation increases TH activity.




Figure 3. The structure of TH

The structure of Aromatic amino acid hydroxylases and TH **A** | Aromatic amino acid hydroxylases share homology in their structure and consist of identical subunits with a 3-domain organization. The enzymes phenylalanine- tryptophan- and tyrosine-hydroxylase contain an N-terminal regulatory domain, central catalytic domain, and C-terminal oligomerization domain. **B** | The regulatory domain of TH can be phosphorylated at serine (S or Ser) residues at position 19 (Ser19), 31 (Ser31) and 40 (Ser40), conserved over species. Position 8 (Ser08), indicated in black is not conserved in humans as a threonine (T) can be found in that position.

Ser40 phosphorylation

Many protein kinases are known to phosphorylate TH at Ser40. It has been widely described that protein kinase A (PKA) can phosphorylate TH at Ser40^{164,172,174,177,179,181,184,191–206}. Also, activation of protein kinase C (PKC), in response to phorbol esters or phospholipase C, leads directly or indirectly to an increase of TH phosphorylation at Ser40^{207–209}. Third, Calcium calmodulin-dependent protein kinase (CAMKII) was also confirmed as an in vitro TH Ser40 kinase²¹⁰. Interestingly, a role for protein kinase G (PKG) on TH phosphorylation was suggested^{211,212}. In bovine adrenal chromaffin cells increased PKG activity, produced significant increases in phosphorylation of TH. Inhibition of PKG, confirmed that the increased phosphorylation was mediated by PKG. When both PKA and PKG signaling routes were activated in this experiment, an additive effect on TH phosphorylation was not observed, suggesting that PKA and PKG phosphorylates the same serine residue. However, the target serine site is never shown directly²¹². PKG shares the same consensus phosphorylation motif with PKA^{212–214}, and such it is in general hard to discriminate between PKA and PKG substrates. It is therefore highly likely that PKG may also control TH Ser40 phosphorylation in a parallel route.

Ser31 phosphorylation

The extracellular signal-regulated protein kinases 1 and 2 (ERK1/2)^{180,181,215,216} and cyclin-dependent kinase 5 (CDK5)^{182,217,218} are known to phosphorylate TH at Ser31 both in vitro and in situ. The direct effects of TH phosphorylation at Ser31 on enzyme activity are modest and the increased TH activity is believed to be due to a decrease in Km value for the cofactor BH4 rather than the dissociation of inhibitory CAs¹⁷⁵. In addition, TH stability was reported to be decreased by inhibition of CDK5-induced Ser31 phosphorylation¹⁸², whereas additional data show that Ser31 phosphorylation targets TH to vesicles for transport along microtubules from the soma to the distal parts of neurites¹⁸³.

Ser19 phosphorylation

Calcium calmodulin-dependent protein kinase (CAMKII) has been reported to not only phosphorylate TH at Ser40 but also Ser19 in situ^{189,219}. Also, p38-regulated/activated protein kinase (PRAK) was found to phosphorylate TH Ser19¹⁸⁹. Next, stability has been correlated with the phosphorylation state of Ser19, which allows binding of 14-3-3, followed by decreased proteolysis by trypsin¹⁸⁸. Binding of 14-3-3 also promotes TH activity, by protecting TH from being dephosphorylated^{189,190,220}.

Figure 4 demonstrates all described protein kinases in various experimental set-ups that increase phosphorylation of its specific TH serine site.




Figure 4. Protein kinase-mediated phosphorylation of TH

Activation of TH is mediated by phosphorylation of serine residues in its amino terminal regulatory domain. This illustration depicts a selection of protein kinases that are found to phosphorylate Th in vitro and in situ in several studies. Phosphorylation results in several functionalities such as increased activity/stability and subcellular localization. Additional protein kinases could be added to the list in future research. *Abbreviations: CAMKII, calcium- and calmodulin stimulated protein kinase II; CDK5, cyclin-dependent kinase 5; ERK1/2, extracellular signal-regulated protein kinase 1/2; PKA, protein kinase A; PKC, protein kinase C; PKG?, protein kinase G; p38-regulated/activated protein kinase, PRAK.*

Hierarchical phosphorylation

Next to the role of each individual TH serine residue has, they can affect the extent of phosphorylation of the other serine residues. This interdependence of phosphorylation sites has been explored in a number of studies^{169,183,187,221–224} and has resulted in a hypothesis describing hierarchical phosphorylation. Overall, Ser19 and Ser31 phosphorylation has been shown to increase the phosphorylation rate of Ser40^{169,187,222,223,225}.

Lehmann *and colleagues* (2006) were the first to describe hierarchical phosphorylation. They increased phosphorylation of Ser19 and Ser31 by angiotensin II (AngII) of purified TH, which increased the rate of phosphorylation of Ser40. This was evident when the reaction did not include dopamine. Therefore, they suggest that the role of Ser19 and Ser31 phosphorylation in dopamine-free TH is to increase the rate of rephosphorylation of Ser40 of TH after it has been dephosphorylated. Also in adrenal chromaffin cells, pre-incubation with AngII increased Th Ser40 phosphorylation by forskolin almost 2-fold. Added to these findings, downregulation of Ser31 phosphorylation by using an ERK1/2 inhibitor decreased basal Ser40 phosphorylation by 50% ¹⁶⁵.

Thus, Ser19 and Ser31 are suggested to indirectly stimulate TH catalytic activity by increasing the rate of Ser40 phosphorylation by its upstream kinase ²²².

Upstream of PKA: adenylyl cyclases and G-protein coupled receptors

In short, TH activity is regulated by kinase phosphorylation of serine residues in the regulatory domain. Out of the upstream kinases, PKA is the most abundant described Ser40 kinase ^{174,175,191}. Inactive PKA is a heterodimer of 2 regulatory subunits bound to 2 catalytic subunits. The regulatory subunit possesses a pseudo-substrate which occupies the substrate binding pocket of the catalytic subunit, preventing activity towards other substrates. The key second messenger required for activation of PKA, cyclic adenosine monophosphate (cAMP), is produced by the conversion of adenosine triphosphate (ATP) to cAMP by adenylyl cyclases (AC) ²²⁶. Upon binding of cAMP to the regulatory subunit, the regulatory and catalytic subunit dissociate. The free catalytic subunit can now phosphorylate a wide array of downstream targets ^{227–229}. In mammals, ACs can be divided into AC1-10 and are expressed throughout the brain ^{230–234}, and peripheral regions ²³⁴. Besides activating PKA, cAMP can interact with multiple additional downstream effectors such as exchange protein activated by cyclic AMP (Epac), cAMP-regulated cyclic nucleotide phosphodiesterases (PDEs) and cyclic nucleotide gated (CNG) channels ^{227–229,235,236}.

Most ACs, except soluble AC (AC10 or sAC) are coupled to G-protein coupled receptors (GPCRs) which can either stimulate or inhibit AC activity. The GPCRs mode of action is primarily activating heterotrimeric G proteins composed a complex of α , β , and γ subunits. GTP binding leads to a conformational change in $G\alpha$, promoting dissociation of the $G\alpha$ and $G\beta\gamma$ subunits. Each of these units can in turn modulate the activity of effector proteins. $G\alpha$ proteins are coupled to adenylyl cyclase. $G\beta\gamma$ subunits can play a role to recruit proteins to the membrane or modulate the activity of kinases, ion channels, or phospholipases ^{237,238}.

The $G\alpha$ can be stimulatory or inhibitory (G_s and G_i , respectively) and therefore increase AC activity or inhibit AC activity. $G\beta\gamma$ can indirectly modulate AC activity, however this is much lower extend as compared to $G\alpha$ ²³⁹. GPCRs can be modulated by a wide range of regulatory signals, including hormones and neurotransmitters ^{240–242}. The most obvious GPCRs in the brain dopamine system are dopamine receptors D1-D5 ⁷⁷. D1-like receptors (D1 and D5) are G_s coupled, whereas D2-like receptors (D2, D3 and D4) are G_i coupled. Of these dopamine receptors, D1-D5 are present post-synaptic, whereas D2-like receptors are the only present pre-synaptic ⁷⁶. Importantly, pre-synaptic stimulation of D2 of the nigrostriatal neuron inhibits AC activity, thereby downregulating the phosphorylation and activity of TH in an autoregulatory feedback loop ^{243,244}.

Next to L-DOPA treatment, dopamine receptor agonists are used as a therapy for PD^{67–69}. These agonists directly stimulate dopamine receptors on the post-synaptic membrane of medium spiny neurons (MSNs), bypassing the presynaptic dopamine synthesis, and act on the D2-class dopamine receptors and D1-class receptors activated by dopamine (and rotamers), phenylbenzazepines, tetracyclis and bicyclis²⁴⁵. Originally, they were used as an adjunctive therapy in advanced PD, however they are now implemented in early stages of the disease. However, their use is still a complicated and sometimes a controversial issue because it involves difficult pharmacokinetics, lower efficacy and high incidence of adverse effects^{70–73}. These adverse effects are explained by the wide distribution of dopamine receptor expression within different brain regions, making it not restricted to the striatal neurons that are the main target in PD^{74–77}.

A second group of interesting AC-coupled GPCRs found in the brain are members of GPCR family B or secretin receptor-like GPCRs. These GPCRs are activated by a super family of structurally related peptide hormones which include pituitary adenylate cyclase-activating polypeptide (PACAP), vasoactive intestinal peptide (VIP) secretin, peptide histidine isoleucine/methionine (PHI/PHM), peptide histidine valine (PHV) and glucagon-like peptides^{246–249}. Some of these peptide hormones are found to increase TH activity in various experiments^{204,248–259}. Therefore, a specifically expressed GPCR in a dopamine neuron that is positively coupled to an AC or is a potential therapeutic target as it may lead to increased TH activity (Fig. 5, right segment).

Parallel route: natriuretic peptide receptors

Interestingly, besides the well described cAMP-PKA pathway, a parallel pathway involving the natriuretic peptide receptor family has been shown to control TH activity. Instead of signaling via cAMP, it is mediated through alterations of second messenger cyclic guanosine monophosphate (cGMP)²⁶⁰.

In mammals, there are three known natriuretic peptide receptors (NPRs), namely NPR-A/GC-A, NPR-B/GC-B, and NPR-C/Clearance receptor that are bound by Atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), and C-type natriuretic peptide (CNP), respectively. The other members of the family are GC-C, a receptor for the intestinal guanylin family of peptides, and Ret-GC-1 and Ret-GC-2, receptors in the retina that regulate the photoreceptor dark cycle^{242,261–266}. These receptors, except from NPR-C are unique in the sense that they have an extracellular ligand binding domain that is directly coupled to an intracellular guanylate cyclase domain. NPR-C does not possess intrinsic enzyme activity as it lacks the intracellular guanylate cyclase domain. Upon activation of the cyclase, cGMP is catalyzed from GTP regulating activity of a variety of intracellular effector targets including PKG, Cyclic nucleotide-gated (CNG) channels and cGMP-dependent PDEs^{267,268}. Besides these so-called particulate guanylyl cyclases (pGC), the guanylate cyclase domain can also be expressed in the cytoplasm without an extracellular ligand binding domain, the soluble guanylate cyclases (sGC). Ligands for sGC include nitric oxide (NO) and carbon monoxide (CO). Activation of NPRs, that are present in the brain, have been described to be associated with increased TH activity when induced by natriuretic peptides^{212,269,270}. Thus, a specifically expressed pGC or sGC in a dopamine neuron is another potential therapeutic target as it may lead to increased TH activity (Fig. 5, left segment).




Figure 5: Cyclic nucleotide-dependent activation of TH

Proposed signaling routes on TH activation after activation of AC-coupled GPCRs, pGCs or sGCs. The targets are activated by an exogenous ligand, which leads to intracellular catalysis of secondary messengers cAMP or cGMP. Elevated levels of cAMP or cGMP directly activate its respective protein kinase, that phosphorylates TH at Ser40, boosting TH activity and dopamine biosynthesis. *Abbreviations: AADC, aromatic amino acid decarboxylase; AC, adenylyl cyclase; pGC, particulate guanylyl cyclase; sGC, soluble guanylyl cyclase; G-protein-coupled receptor (GPCR); Gs, large guanine-nucleotide-binding regulatory protein α stimulatory subunit; TH, Tyrosine hydroxylase.*

Scope and aim of this thesis

In **this chapter**, we discussed the major drawbacks of current therapies used in movement disorders such as PD. Progressive degeneration of dopamine neurons leads to loss of dopamine signaling in the basal ganglia and substantia nigra. Dopamine production is targeted by exogenous application of L-DOPA and is successful for the early stages of the disease. However, L-DOPA therapy leads to severe side-effects, such as L-DOPA induced dyskinesias and atypical extranigral actions. Also, the therapeutic window in which the therapeutic response is effective narrows in later stages of the disease. Subsequently, the use of dopamine agonists has some major drawbacks, as the efficacy of these therapeutics diminishes when disease progresses and aspecificity of expression towards different brain areas, such as the cortical regions. To increase dopamine bioavailability and release to commemorate the loss of dopamine signaling and relieve symptoms, we propose a different route. We aim to target TH, which is the rate-limiting enzyme in dopamine synthesis. As TH is the limiting enzyme in the reaction, and dopamine interacts with the catalytic region of TH to decrease its activity, increasing the activity of the enzyme could accelerate dopamine biosynthesis in an endogenous manner. We propose that increasing endogenous enzyme activity specifically in nigrostriatal neurons by activation of upstream cAMP/cGMP routes, will lead to enhanced local dopamine production in the target area of interest, which reduces potential side effects and counteracts the dopamine depletion.

In **chapter 2**, we first revisited the AC-cAMP-PKA signaling route on Th Ser40 and Ser31 phosphorylation in dopaminergic MN9D cells. We confirm that various cAMP analogs increase Th Ser40 phosphorylation. Interestingly, Ser31 phosphorylation was downregulated in response to the same second messengers.

Using small chemical kinase inhibitors, we show crosstalk between the upstream kinases of Ser40 and Ser31 pathway. Finally, we investigated hierarchical phosphorylation of Th, as it is proposed that phosphorylation of one serine could affect the rate of phosphorylation of the other serine. With the use of phospho-mimetic mutants, we show that phosphorylation of Th at Ser40 is required for phosphorylation of Ser31, whereas we find no evidence to support the reported claim this is the other way around. This suggests Th Ser40 could be the most relevant phosphorylation site increasing the enzyme's activity as well as function.

In the **3rd chapter**, we describe an ex vivo approach to investigate Th phosphorylation in microdissected striatal or midbrain mouse brain slices. This was performed in order to provide a more detailed picture on upstream signaling routes of Th in an ex vivo setting. The distribution of Th Ser31 and Ser40 phosphorylation in these micro-dissected areas were examined, and cAMP-dependent routes on Th phosphorylation were explored. Using our ex vivo model, we demonstrated abundant expression of (phosphorylated) Th protein present in the corpus striatum, and the ability to modulate Th Ser40 phosphorylation via cAMP-dependent routes. We first revisited PKA and ERK1/2 crosstalk in the mouse striatum. Using a library of kinase specific small inhibitors, we demonstrated a trend towards downregulated Ser40 phosphorylation levels mediated by PKA. However, we show that ERK1/2 is upstream of Th Ser31 phosphorylation. In sum, we were able to increase Th Ser40 in microdissected mouse striatal slices by inducing cAMP-dependent signaling routes.

Chapter 4 was focused on the effect of catecholamines L-DOPA and dopamine on Th phosphorylation. The influence of increased levels of L-DOPA and dopamine was investigated on Th Ser40 phosphorylation in dopamine terminals in the mouse striatum. L-DOPA downregulates Ser40 phosphorylation, suggesting an inhibitory feedback mechanism on Th activity. Possibly, these effects are caused by an autoregulatory feedback inhibition route mediated by D2R. Indeed, dopamine application downregulated Ser40 phosphorylation as well. Strikingly, the negative effects of L-DOPA on Th phosphorylation could be reversed by activating cAMP signaling. Altogether, we propose that an endogenous approach to boost dopamine synthesis by targeting upstream signaling pathway routes of Th phosphorylation could especially be effective in early PD stages and may even boost the effectiveness of L-DOPA therapy.

In **chapter 5**, we investigated the guanylyl cyclase receptor (GC-C, or *GUCY2C* gene) as a potential upstream target for Th phosphorylation in dopaminergic neurons. Using a set of endogenous peptide ligands, together with custom peptide analogs, we demonstrate that targeting the GC-C receptor is a successful method for increasing Th Ser40 phosphorylation in dopamine neurons. As GC-C is specifically and exclusively expressed in dopaminergic midbrain neurons, targeting this receptor in vivo may be considered as a possible therapeutic target to increase dopamine production in PD.

Finally, the main findings from our experimental chapters are summarized and implications are discussed in **chapter 6**.

References

1. Tysnes, O. B. & Storstein, A. Epidemiology of Parkinson's disease. *Journal of Neural Transmission* 124, 901–905 (2017).
2. von Campenhausen, S. et al. Prevalence and incidence of Parkinson's disease in Europe. *European Neuropsychopharmacology* 15, 473–490 (2005).
3. de Lau, L. M. & Breteler, M. M. Epidemiology of Parkinson's disease. *Lancet Neurology* 5, 525–535 (2006).
4. Rajput, A. H. Frequency and Cause of Parkinson's Disease. *Canadian Journal of Neurological Sciences* 19, 103–107 (1992).
5. Tagliaferro, P. & Burke, R. E. Retrograde Axonal Degeneration in Parkinson Disease. *Journal of Parkinson's Disease* 6, 1–15 (2016).
6. Dauer, W. & Przedborski, S. Parkinson's disease: Mechanisms and models. *Neuron* 39, 889–909 (2003).
7. Gerfen, C. R. & Surmeier, D. J. Modulation of Striatal Projection Systems by Dopamine. *Annual Review of Neuroscience* 34, 441–466 (2011).
8. Björklund, A. & Dunnett, S. B. Dopamine neuron systems in the brain: an update. *Trends in Neurosciences* 30, 194–202 (2007).
9. Ikemoto, S., Yang, C. & Tan, A. Basal ganglia circuit loops, dopamine and motivation: A review and enquiry. *Behavioural Brain Research* 290, 17–31 (2015).
10. Caminiti, S. P. et al. Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease. *NeuroImage: Clinical* 14, 734–740 (2017).
11. Moustafa, A. A. et al. Motor symptoms in Parkinson's disease: A unified framework. *Neuroscience and Biobehavioral Reviews* 68, 727–740 (2016).
12. Sveinbjörnsdóttir, S. The clinical symptoms of Parkinson's disease. *Journal of Neurochemistry* 139, 318–324 (2016).
13. Kalia, L. v. & Lang, A. E. Parkinson's disease. *Lancet* 386, 896–912 (2015).
14. Han, J. W. et al. Psychiatric Manifestation in Patients with Parkinson's Disease. *Journal of Korean Medical Science* 33, (2018).
15. Zesiewicz, T. A., Sullivan, K. L. & Hauser, R. A. Nonmotor symptoms of Parkinson's disease. *Expert Review of Neurotherapeutics* 6, 1811–1822 (2006).
16. Cheng, H. C., Ulane, C. M. & Burke, R. E. Clinical progression in Parkinson disease and the neurobiology of axons. *Annals of Neurology* 67, 715–725 (2010).
17. Berg, D. et al. MDS research criteria for prodromal Parkinson's disease. *Movement Disorders* 30, 1600–1611 (2015).
18. Heinzl, S. et al. Update of the MDS research criteria for prodromal Parkinson's disease. *Movement Disorders* 34, 1464–1470 (2019).
19. Hustad, E. & Aasly, J. O. Clinical and Imaging Markers of Prodromal Parkinson's Disease. *Frontiers in Neurology* 11, 395 (2020).
20. Lill, C. M. Genetics of Parkinson's disease. *Molecular and Cellular Probes* 30, 386–396 (2016).
21. Shulman, J. M., de Jager, P. L. & Feany, M. B. Parkinson's disease: Genetics and pathogenesis. *Annual Review of Pathology: Mechanisms of Disease* 6, 193–222 (2011).

22. Martin, I., Dawson, V. L. & Dawson, T. M. Recent advances in the genetics of parkinson's disease. *Annual Review of Genomics and Human Genetics* 12, 301–325 (2011).
23. Corti, O., Lesage, S. & Brice, A. What genetics tells us about the causes and mechanisms of Parkinson's disease. *Physiological Reviews* 91, 1161–1218 (2011).
24. Exner, N., Lutz, A. K., Haass, C. & Winklhofer, K. F. Mitochondrial dysfunction in Parkinson's disease: Molecular mechanisms and pathophysiological consequences. *EMBO Journal* 31, 3038–3062 (2012).
25. Kalinderi, K., Bostantjopoulou, S. & Fidani, L. The genetic background of Parkinson's disease: current progress and future prospects. *Acta Neurologica Scandinavica* 134, 314–326 (2016).
26. Verstraeten, A., Theuns, J. & van Broeckhoven, C. Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. *Trends in Genetics* 31, 140–149 (2015).
27. Cannon, J. R. & Greenamyre, J. T. Gene-environment interactions in Parkinson's disease: Specific evidence in humans and mammalian models. *Neurobiology of Disease* 57, 38–46 (2013).
28. Castillo, S., Muñoz, P., Behrens, M. I., Diaz-Grez, F. & Segura-Aguilar, J. On the Role of Mining Exposure in Epigenetic Effects in Parkinson's Disease. *Neurotoxicity Research* 32, 172–174 (2017).
29. Pouchieu, C. et al. Pesticide use in agriculture and Parkinson's disease in the AGRICAN cohort study. *International Journal of Epidemiology* 47, 299–310 (2018).
30. Pezzoli, G. & Cereda, E. Exposure to pesticides or solvents and risk of Parkinson disease. *Neurology* 80, 2035–2041 (2013).
31. Chen, H. et al. Consumption of dairy products and risk of parkinson's disease. *American Journal of Epidemiology* 165, 998–1006 (2007).
32. Goldman, S. M. et al. Head injury and Parkinson's disease risk in twins. *Annals of Neurology* 60, 65–72 (2006).
33. Tanner, C. M. Advances in environmental epidemiology. *Movement Disorders* 25, (2010).
34. Fleming, S. M. Mechanisms of Gene-Environment Interactions in Parkinson's Disease. *Current environmental health reports* 4, 192–199 (2017).
35. Armstrong, M. J. & Okun, M. S. Diagnosis and Treatment of Parkinson Disease: A Review. *JAMA - Journal of the American Medical Association* 323, 548–560 (2020).
36. Hufton, S. E., Jennings, I. G. & Cotton, R. G. H. Structure and function of the aromatic amino acid hydroxylases. *Biochemical Journal* 311, 353–366 (1995).
37. Fitzpatrick, P. F. The aromatic amino acid hydroxylases. *Advances in Enzymology and Related Areas of Molecular Biology* 74, 235–294 (2000).
38. Ahlskog, J. E. Medical treatment of Parkinson's disease. *Comprehensive Therapy* 15, 53–59 (1989).
39. Khor, S.-P. & Hsu, A. The Pharmacokinetics and Pharmacodynamics of Levodopa in the Treatment of Parkinsons Disease. *Current Clinical Pharmacology* 2, 234–243 (2007).
40. Nyholm, D. Pharmacokinetic optimisation in the treatment of Parkinson's disease: An update. *Clinical Pharmacokinetics* 45, 109–136 (2006).

41. Nutt, J. G. & Holford, N. H. G. The response to levodopa in Parkinson's disease: Imposing pharmacological law and order. *Annals of Neurology* 39, 561–573 (1996).
42. Uchino, H. et al. Transport of Amino Acid-Related Compounds Mediated by L-Type Amino Acid Transporter 1 (LAT1): Insights Into the Mechanisms of Substrate Recognition. *Molecular Pharmacology* 61, 729–737 (2002).
43. Kido, Y. et al. Molecular and functional identification of large neutral amino acid transporters LAT1 and LAT2 and their pharmacological relevance at the blood-brain barrier. *Journal of Pharmacy and Pharmacology* 53, 497–503 (2001).
44. Upadhyaya, M. A., Shelkar, G. P., Subhedar, N. K. & Kokare, D. M. CART modulates the effects of levodopa in rat model of Parkinson's disease. *Behavioural Brain Research* 301, 262–272 (2016).
45. Chagraoui, A. et al. L-DOPA in Parkinson's Disease: Looking at the "False" Neurotransmitters and Their Meaning. *International Journal of Molecular Sciences* 2020, Vol. 21, Page 294 21, 294 (2019).
46. de Deurwaerdère, P., di Giovanni, G. & Millan, M. J. Expanding the repertoire of L-DOPA's actions: A comprehensive review of its functional neurochemistry. *Progress in Neurobiology* 151, 57–100 (2017).
47. Miller, D. W. & Abercrombie, E. D. Role of High-Affinity Dopamine Uptake and Impulse Activity in the Appearance of Extracellular Dopamine in Striatum After Administration of Exogenous L-DOPA. *Journal of Neurochemistry* 72, 1516–1522 (1999).
48. Abercrombie, E. D., Bonatz, A. E., & Zigmond, M. J. Effects of L-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. *Brain research*, 525, 36-44 (1990).
49. Olanow, C. W. & Tatton, W. G. Etiology and pathogenesis of Parkinson's disease. *Annual Review of Neuroscience* 22, 123–144 (1999).
50. Karobath, M., Díaz, J. L. & Huttunen, M. O. The effect of L-dopa on the concentrations of tryptophan, tyrosine and serotonin in rat brain. *European Journal of Pharmacology* 14, 393–396 (1971).
51. Hinz, M., Stein, A. & Uncini, T. Amino acid management of Parkinson's disease: A case study. *International Journal of General Medicine* 4, 165–174 (2011).
52. Wade, D. N., Mearrick, P. T. & Morris, J. L. Active transport of L-Dopa in the intestine. *Nature* 242, 463–465 (1973).
53. Gainetdinov, R. R., Hoener, M. C. & Berry, M. D. Trace amines and their receptors. *Pharmacological Reviews* 70, 549–620 (2018).
54. Asanuma, M., Miyazaki, I., Murakami, S., Diaz-Corrales, F. J. & Ogawa, N. Striatal Astrocytes Act as a Reservoir for L-DOPA. *PLoS ONE* 9, e106362 (2014).
55. Stansley, B. & Yamamoto, B. L-Dopa and Brain Serotonin System Dysfunction. *Toxics* 3, 75–88 (2015).
56. Carta, M. & Tronci, E. Serotonin system implication in L-DOPA-induced dyskinesia: From animal models to clinical investigations. *Frontiers in Neurology* 5 MAY, (2014).
57. Jenner, P. Molecular mechanisms of L-DOPA-induced dyskinesia. *Nature Reviews Neuroscience* 9, 665–677 (2008).

58. Kozina, E. A., Kim, A. R., Kurina, A. Y. & Ugrumov, M. v. Cooperative synthesis of dopamine by non-dopaminergic neurons as a compensatory mechanism in the striatum of mice with MPTP-induced Parkinsonism. *Neurobiology of Disease* 98, 108–121 (2017).
59. Nevalainen, N., Af Bjerkén, S., Gerhardt, G. A. & Strömberg, I. Serotonergic nerve fibers in L-DOPA-derived dopamine release and dyskinesia. *Neuroscience* 260, 73–86 (2014).
60. Bishop, C. et al. Serotonin transporter inhibition attenuates L-DOPA-induced dyskinesia without compromising L-DOPA efficacy in hemi-parkinsonian rats. *European Journal of Neuroscience* 36, 2839–2848 (2012).
61. Conti, M. M. et al. Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats. *Neuropharmacology* 77, 1–8 (2014).
62. Kuan, W. L., Zhao, J. W. & Barker, R. A. The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. *Psychopharmacology (Berl)* 197, 279–293 (2008).
63. Muñoz, A. et al. Combined 5-HT_{1A} and 5-HT_{1B} receptor agonists for the treatment of L-DOPA-induced dyskinesia. *Brain* 131, 12 (2008).
64. Thanvi, B., Lo, N. & Robinson, T. Levodopa-induced dyskinesia in Parkinson's disease: Clinical features, pathogenesis, prevention and treatment. *Postgraduate Medical Journal* 83, 384–388 (2007).
65. Berke, J. D., Paletzki, R. F., Aronson, G. J., Hyman, S. E. & Gerfen, C. R. A complex program of striatal gene expression induced by dopaminergic stimulation. *Journal of Neuroscience* 18, 5301–5310 (1998).
66. Boyce, S., Rupniak, N. M. J., Steventon, M. J. & Iversen, S. D. Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys. *Clinical Neuropharmacology* 13, 448–458 (1990).
67. Francis Lam, Y. W. Clinical pharmacology of dopamine agonists. *Pharmacotherapy* 20, (2000).
68. Contin, M., Riva, R., Albani, F. & Baruzzi, A. Pharmacokinetic optimisation of dopamine receptor agonist therapy for Parkinson's disease. *CNS Drugs* 14, 439–455 (2000).
69. Clarke, C. E. Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease. *Lancet Neurology* 3, 466–474 (2004).
70. Poewe, W. Should treatment of Parkinson's disease be started with a dopamine agonist? *Neurology* 51, (1998).
71. Olanow, C. W. The role of dopamine agonists in the treatment of early Parkinson's disease. *Neurology* 58, (2002).
72. Wachtel, H. Antiparkinsonian dopamine agonists: a review of the pharmacokinetics and neuropharmacology in animals and humans. *Journal of Neural Transmission - Parkinsons Disease and Dementia Section* 3, 151–201 (1991).
73. Rascol, O. Dopamine agonists: What is the place of the newer compounds in the treatment of Parkinson's disease? *Journal of Neural Transmission, Supplement* 33–45 (1999).
74. Weiner, D. M. et al. D₁ and D₂ dopamine receptor mRNA in rat brain. *Proceedings of the National Academy of Sciences* 88, 1859–1863 (1991).

75. Douma, E. H. & de Kloet, E. R. Stress-induced plasticity and functioning of ventral tegmental dopamine neurons. *Neuroscience and Biobehavioral Reviews* 108, 48–77 (2020).
76. Beaulieu, J. M. & Gainetdinov, R. R. The physiology, signaling, and pharmacology of dopamine receptors. *Pharmacological Reviews* 63, 182–217 (2011).
77. Ayano, G. Dopamine: Receptors, Functions, Synthesis, Pathways, Locations and Mental Disorders: Review of Literatures. *Journal of Mental Disorders and Treatment* 2, (2016).
78. Coune, P. G., Schneider, B. L. & Aebischer, P. Parkinson's disease: Gene therapies. *Cold Spring Harbor Perspectives in Medicine* 2, (2012).
79. Belin, A. C. & Westerlund, M. Parkinson's disease: A genetic perspective. *FEBS Journal* 275, 1377–1383 (2008).
80. Maiti, P., Manna, J., Dunbar, G. L., Maiti, P. & Dunbar, G. L. Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments. *Translational Neurodegeneration* 6, (2017).
81. Bartus, R. T., Weinberg, M. S. & Samulski, R. J. Parkinson's disease gene therapy: Success by design meets failure by efficacy. *Molecular Therapy* 22, 487–497 (2014).
82. Meiser, J., Weindl, D. & Hiller, K. Complexity of dopamine metabolism. *Cell Communication and Signaling* 11, (2013).
83. Mittermeyer, G. et al. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. *Human Gene Therapy* 23, 377–381 (2011).
84. Eberling, J. L., Jagust, W. J., Christine, C. W., Starr, P., Larson, P., Bankiewicz, K. S., & Aminoff, M. J. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. *Neurology*, 70(21), 1980-1983 (2008).
85. Hadaczek, P. et al. Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. *Molecular Therapy* 18, 1458–1461 (2010).
86. Forsayeth, J. R. et al. A Dose-Ranging Study of AAV-hAADC Therapy in Parkinsonian Monkeys. *Molecular Therapy* 14, 571–577 (2006).
87. Azzouz, M. et al. Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model. *Journal of Neuroscience* 22, 10302–10312 (2002).
88. Palfi, S. et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: A dose escalation, open-label, phase 1/2 trial. *The Lancet* 383, 1138–1146 (2014).
89. Jarraya, B. et al. Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. *Science Translational Medicine* 1, (2009).
90. Muramatsu, S. The current status of gene therapy for Parkinson's disease. *Ann Neurosci* 17, (2010).
91. Caudle, W. M., Colebrooke, R. E., Emsen, P. C. & Miller, G. W. Altered vesicular dopamine storage in Parkinson's disease: a premature demise. *Trends in Neurosciences* 31, 303–308 (2008).
92. Chen, L. et al. Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. *Journal of Neuroscience* 28, 425–433 (2008).

93. Man, J. H. K., Groenink, L. & Caiazzo, M. Cell reprogramming approaches in gene- and cell-based therapies for Parkinson's disease. *Journal of Controlled Release* 286, 114–124 (2018).
94. Backlund, E. O., Granberg, P. O. & Hamberger, B. Transplantation of adrenal medullary tissue to striatum in parkinsonism. *Fernstrom Foundation Series VOL. 5*, 551–556 (1985).
95. Lindvall, O. et al. Transplantation in Parkinson's disease: Two cases of adrenal medullary grafts to the putamen. *Annals of Neurology* 22, 457–468 (1987).
96. Freed, C. R. et al. Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease. *New England Journal of Medicine* 344, 710–719 (2001).
97. Lindvall, O. Treatment of Parkinson's disease using cell transplantation. *Philosophical Transactions of the Royal Society B: Biological Sciences* 370, (2015).
98. Kim, J. H. et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. *Nature* 418, 50–56 (2002).
99. Thomson, J. A. Embryonic stem cell lines derived from human blastocysts. *Science* (1979) 282, 1145–1147 (1998).
100. Kirkeby, A. et al. Generation of Regionally Specified Neural Progenitors and Functional Neurons from Human Embryonic Stem Cells under Defined Conditions. *Cell Reports* 1, 703–714 (2012).
101. Zhang, S. C., Li, X. J., Johnson, M. A. & Pankratz, M. T. Human embryonic stem cells for brain repair? *Philosophical Transactions of the Royal Society B: Biological Sciences* 363, 87–99 (2008).
102. Roybon, L., Christophersen, N. S., Brundin, P. & Li, J. Y. Stem cell therapy for Parkinson's disease: Where do we stand? *Cell and Tissue Research* 318, 261–273 (2004).
103. Fu, M. H. et al. Stem cell transplantation therapy in Parkinson's disease. *Springerplus* 4, (2015).
104. Kriks, S. et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. *Nature* 480, 547–551 (2011).
105. González, C., Bonilla, S., Isabel Flores, A., Cano, E. & Liste, I. An Update on Human Stem Cell-Based Therapy in Parkinson's Disease. *Current Stem Cell Research & Therapy* 11, 561–568 (2016).
106. Barker, R. A., Barrett, J., Mason, S. L. & Björklund, A. Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease. *The Lancet Neurology* 12, 84–91 (2013).
107. Fitzpatrick, K. M., Raschke, J. & Emborg, M. E. Cell-based therapies for Parkinson's disease: Past, present, and future. *Antioxidants and Redox Signaling* 11, 2189–2208 (2009).
108. Pfisterer, U. et al. Direct conversion of human fibroblasts to dopaminergic neurons. *Proceedings of the National Academy of Sciences* 108, 10343–10348 (2011).
109. Masserdotti, G., Gascón, S. & Götz, M. Direct neuronal reprogramming: Learning from and for development. *Development (Cambridge)* 143, 2494–2510 (2016).
110. Hallett, P. J. et al. Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease. *Cell Stem Cell* 16, 269–274 (2015).

111. Sundberg, M. et al. Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. *Stem Cells* 31, 1548–1562 (2013).
112. Kikuchi, T. et al. Survival of human induced pluripotent stem cell-derived midbrain dopaminergic neurons in the brain of a primate model of Parkinson's disease. *Journal of Parkinson's Disease* 1, 395–412 (2011).
113. Doi, D. et al. Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation. *Stem Cell Reports* 2, 337–350 (2014).
114. Turner, M. et al. Toward the development of a global induced pluripotent stem cell library. *Cell Stem Cell* 13, 382–384 (2013).
115. Lindholm, D. et al. Current disease modifying approaches to treat Parkinson's disease. *Springer* 73, 1365–1379 (2016).
116. Paul, G. & Sullivan, A. M. Trophic factors for Parkinson's disease: Where are we and where do we go from here? *European Journal of Neuroscience* 49, 440–452 (2019).
117. Zhu, Y. et al. Transforming Growth Factor- β 1 Increases Bad Phosphorylation and Protects Neurons Against Damage. *Journal of Neuroscience* 22, 3898–3909 (2002).
118. Venderova, K. & Park, D. S. Programmed cell death in Parkinson's disease. *Cold Spring Harbor Perspectives in Medicine* 2, (2012).
119. van der Heide, L. P. & Smidt, M. P. The BCL2 code to dopaminergic development and Parkinson's disease. *Trends in Molecular Medicine* 19, 211–216 (2013).
120. Blaschko, H. Biochemistry of catecholamines — The biochemical method. *Journal of Chromatography A* 103, 404 (1975).
121. Roberts, K. M. & Fitzpatrick, P. F. Mechanisms of tryptophan and tyrosine hydroxylase. *IUBMB Life* 65, 350–357 (2013).
122. Kleppe, R., Uhlemann, K., Knappskog, P. M. & Haavik, J. Urea-induced Denaturation of Human Phenylalanine Hydroxylase. *Journal of Biological Chemistry* 274, 33251–33258 (1999).
123. Bezem, M. T. et al. Stable preparations of tyrosine hydroxylase provide the solution structure of the full-length enzyme. *Scientific Reports* 6, 1–14 (2016).
124. Fitzpatrick, P. F. Structural insights into the regulation of aromatic amino acid hydroxylation. *Current Opinion in Structural Biology* 35, 1–6 (2015).
125. Flatmark, T. & Stevens, R. C. Structural Insight into the Aromatic Amino Acid Hydroxylases and Their Disease-Related Mutant Forms. *Chemical Reviews* 99, 2137–2160 (1999).
126. Briggs, G. D., Bulley, J. & Dickson, P. W. Catalytic domain surface residues mediating catecholamine inhibition in tyrosine hydroxylase. *Journal of Biochemistry* 155, 183–193 (2014).
127. Waløen, K., Kleppe, R., Martinez, A. & Haavik, J. Tyrosine and tryptophan hydroxylases as therapeutic targets in human disease. *Expert Opinion on Therapeutic Targets* 21, 167–180 (2017).
128. Blau, N., van Spronsen, F. J. & Levy, H. L. Phenylketonuria. *The Lancet* 376, 1417–1427 (2010).
129. Strisciuglio, P. & Concolino, D. New strategies for the treatment of phenylketonuria (PKU). *Metabolites* 4, 1007–1017 (2014).

130. Moens, A. L. & Kass, D. A. Therapeutic potential of tetrahydrobiopterin for treating vascular and cardiac disease. *Journal of Cardiovascular Pharmacology* 50, 238–246 (2007).
131. Nyström, T., Nygren, A. & Sjöholm, Å. Tetrahydrobiopterin increases insulin sensitivity in patients with type 2 diabetes and coronary heart disease. *American Journal of Physiology - Endocrinology and Metabolism* 287, (2004).
132. Ihlemann, N. et al. Tetrahydrobiopterin restores endothelial dysfunction induced by an oral glucose challenge in healthy subjects. *American Journal of Physiology - Heart and Circulatory Physiology* 285, (2003).
133. Cosentino, F. et al. Chronic treatment with tetrahydrobiopterin reverses endothelial dysfunction and oxidative stress in hypercholesterolaemia. *Heart* 94, 487–492 (2008).
134. Levy, H. L. et al. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. *Lancet* 370, 504–510 (2007).
135. Werner, E. R., Gorren, A. C. F., Heller, R., Werner-Felmayer, G. & Mayer, B. Tetrahydrobiopterin and Nitric Oxide: Mechanistic and Pharmacological Aspects. *Experimental Biology and Medicine* 228, 1291–1302 (2003).
136. Thöny, B., Auerbach, G. & Blau, N. Tetrahydrobiopterin biosynthesis, regeneration and functions. *Biochemical Journal* 347, 1–16 (2000).
137. LeWitt, P. A. et al. Tyrosine hydroxylase cofactor (tetrahydrobiopterin) in parkinsonism. *Advances in Neurology* 40, 459–462 (1984).
138. Curtius, H. C., Niederwieser, A., Levine, R. & Müldner, H. Therapeutic efficacy of tetrahydrobiopterin in Parkinson's disease. *Advances in Neurology* 40, 463–466 (1984).
139. Fanet, H., Capuron, L., Castanon, N., Calon, F. & Vancassel, S. Tetrahydrobiopterin (BH4) Pathway: From Metabolism to Neuropsychiatry. *Current Neuropharmacology* 19, 591–609 (2020).
140. Ng, J., Papandreou, A., Heales, S. J. & Kurian, M. A. Monoamine neurotransmitter disorders - Clinical advances and future perspectives. *Nature Reviews Neurology* 11, 567–584 (2015).
141. Willemsen, Michèl A., et al. Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. *Brain* 133, 1810–1822 (2010).
142. Dunkley, P. R. & Dickson, P. W. Tyrosine hydroxylase phosphorylation in vivo. *Journal of Neurochemistry* 149, 706–728 (2019).
143. Haycock, J. W., George, R. J. & Waymire, J. C. In situ phosphorylation of tyrosine hydroxylase in chromaffin cells: Localization to soluble compartments. *Neurochemistry International* 7, 301–308 (1985).
144. Lewis, D. A., Melchitzky, D. S. & Haycock, J. W. Four isoforms of tyrosine hydroxylase are expressed in human brain. *Neuroscience* 54, 477–492 (1993).
145. Grima, B. et al. A single human gene encoding multiple tyrosine hydroxylases with different predicted functional characteristics. *Nature* 326, 707–711 (1987).
146. Kaneda, N. et al. Isolation of a novel cDNA clone for human tyrosine hydroxylase: Alternative RNA splicing produces four kinds of mRNA from a single gene. *Biochemical and Biophysical Research Communications* 146, 971–975 (1987).

147. Shehadeh, J. et al. Expression of tyrosine hydroxylase isoforms and phosphorylation at serine 40 in the human nigrostriatal system in Parkinson's disease. *Neurobiology of Disease* 130, (2019).
148. Tank, A. W., Xu, L., Chen, X., Radcliffe, P. & Sterling, C. R. Post-transcriptional Regulation of Tyrosine Hydroxylase Expression in Adrenal Medulla and Brain. *Annals of the New York Academy of Sciences* 1148, 238–248 (2008).
149. Lenartowski, R. & Goc, A. Epigenetic, transcriptional and posttranscriptional regulation of the tyrosine hydroxylase gene. *International Journal of Developmental Neuroscience* 29, 873–883 (2011).
150. Pasinetti, G. M. et al. Slow changes of tyrosine hydroxylase gene expression in dopaminergic brain neurons after neurotoxin lesioning: a model for neuron aging. *Molecular Brain Research* 13, 63–73 (1992).
151. Pasinetti, G. M. et al. Chronic lesions differentially decrease tyrosine hydroxylase messenger RNA in dopaminergic neurons of the substantia nigra. *Molecular Brain Research* 5, 203–209 (1989).
152. Blanchard, V. et al. Long-Term Induction of Tyrosine Hydroxylase Expression: Compensatory Response to Partial Degeneration of the Dopaminergic Nigrostriatal System in the Rat Brain. *Journal of Neurochemistry* 64, 1669–1679 (1995).
153. Bowyer, J. F. et al. Long-term effects of amphetamine neurotoxicity on tyrosine hydroxylase mRNA and protein in aged rats. *Journal of Pharmacology and Experimental Therapeutics* 286, 1074–1085 (1998).
154. Haavik, J., Blau, N. & Thöny, B. Mutations in human monoamine-related neurotransmitter pathway genes. *Human Mutation* 29, 891–902 (2008).
155. Rao, F. et al. Tyrosine hydroxylase, the rate-limiting enzyme in catecholamine biosynthesis: discovery of common human genetic variants governing transcription, autonomic. *Am Heart Assoc* 116, 993–1006 (2007).
156. Kobayashi, K. & Nagatsu, T. Molecular genetics of tyrosine 3-monoxygenase and inherited diseases. *Biochemical and Biophysical Research Communications* 338, 267–270 (2005).
157. Hoffmann, G. F. et al. Tyrosine hydroxylase deficiency causes progressive encephalopathy and Dopamine-responsive dystonia. *Annals of Neurology* 54, S56–S65 (2003).
158. Lüdecke, B. et al. Recessively inherited L-DOPA-responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene. *Human Molecular Genetics* 5, 1023–1028 (1996).
159. Wevers, R. A. et al. A review of biochemical and molecular genetic aspects of tyrosine hydroxylase deficiency including a novel mutation (291delC). *Journal of Inherited Metabolic Disease* 22, 364–373 (1999).
160. Lüdecke, B., Dworniczak, B. & Bartholomé, K. A point mutation in the tyrosine hydroxylase gene associated with Segawa's syndrome. *Human Genetics* 95, 123–125 (1995).
161. Knappskog, P. M., Flatmark, T., Mallet, J., Ludecke, B. & Bartholomé, K. Recessively inherited L-DOPA-responsive dystonia caused by a point mutation (Q381K) in the tyrosine hydroxylase gene. *Human Molecular Genetics* 4, 1209–1212 (1995).
162. van den Heuvel, L. P. W. J. et al. A common point mutation in the tyrosine hydroxylase gene in autosomal recessive L-DOPA-responsive dystonia in the Dutch population. *Human Genetics* 102, 644–646 (1998).

163. Bräutigam, C. et al. Biochemical hallmarks of tyrosine hydroxylase deficiency. *Clinical Chemistry* 44, 1897–1904 (1998).
164. Kumer, S. C. et al. Intricate regulation of tyrosine hydroxylase activity and gene expression. *Journal of Neurochemistry* 67, 443–462 (1996).
165. Gordon, S. L., Quinsey, N. S., Dunkley, P. R. & Dickson, P. W. Tyrosine hydroxylase activity is regulated by two distinct dopamine-binding sites. *Journal of Neurochemistry* 106, 1614–1623 (2008).
166. Daubner SC, Piper MM. Deletion mutants of tyrosine hydroxylase identify a region critical for heparin binding. *Protein Science* 4, 538–541 (1995).
167. Daubner, S. C., Le, T. & Wang, S. Tyrosine hydroxylase and regulation of dopamine synthesis. *Archives of Biochemistry and Biophysics* 508, 1–12 (2011).
168. Nakashima, A. et al. The mutation of two amino acid residues in the N-terminus of tyrosine hydroxylase (TH) dramatically enhances the catalytic activity in neuroendocrine AtT-20 cells. *Journal of Neurochemistry* 82, 202–206 (2002).
169. Tekin, I., Roskoski, R., Carkaci-Salli, N. & Vrana, K. E. Complex molecular regulation of tyrosine hydroxylase. *Journal of Neural Transmission* 121, 1451–1481 (2014).
170. Fujisawa, H. & Okuno, S. Regulatory mechanism of tyrosine hydroxylase activity. *Biochemical and Biophysical Research Communications* 338, 271–276 (2005).
171. Dickson, P. W. & Briggs, G. D. Tyrosine hydroxylase. Regulation by feedback inhibition and phosphorylation. *Advances in Pharmacology* vol. 68 (2013).
172. Campbell, D. G. et al. Identification of Four Phosphorylation Sites in the N-terminal Region of Tyrosine Hydroxylase*. *Journal of Biological Chemistry* 261, 10489–10492 (1986).
173. Haycock, J. W. & Wakade, A. R. Activation and Multiple-Site Phosphorylation of Tyrosine Hydroxylase in Perfused Rat Adrenal Glands. *Journal of Neurochemistry* 58, 57–64 (1992).
174. Haycock, J. W. Phosphorylation of tyrosine hydroxylase in situ at serine 8, 19, 31, and 40. *Journal of Biological Chemistry* 265, 11682–11691 (1990).
175. Dunkley, P. R., Bobrovskaya, L., Graham, M. E., von Nagy-Felsobuki, E. I. & Dickson, P. W. Tyrosine hydroxylase phosphorylation: regulation and consequences. *Journal of Neurochemistry* 91, 1025–1043 (2004).
176. Royo, M., Fitzpatrick, P. F. & Daubner, S. C. Mutation of regulatory serines of rat tyrosine hydroxylase to glutamate: Effects on enzyme stability and activity. *Archives of Biochemistry and Biophysics* 434, 266–274 (2005).
177. Harada, K., Wu, J., Haycock, J. W. & Goldstein, M. Regulation of L-DOPA Biosynthesis by Site-Specific Phosphorylation of Tyrosine Hydroxylase in AtT-20 Cells Expressing Wild-Type and Serine 40-Substituted Enzyme. *Journal of Neurochemistry* 67, 629–635 (2002).
178. Andersson, K. K., Cox, D. D., Que, L., Flatmark, T. & Haavik, J. Resonance Raman studies on the blue-green-colored bovine adrenal tyrosine 3-monooxygenase (tyrosine hydroxylase). Evidence that the feedback inhibitors adrenaline and noradrenaline are coordinated to iron. *Journal of Biological Chemistry* 263, 18621–18626 (1988).
179. Salvatore, M. F., Waymire, J. C. & Haycock, J. W. Depolarization-stimulated catecholamine biosynthesis: Involvement of protein kinases and tyrosine hydroxylase phosphorylation sites in situ. *Journal of Neurochemistry* 79, 349–360 (2001).
180. Halloran, S. M. & Vulliet, P. R. Microtubule-associated Protein Kinase-2 Phosphorylates and Activates Tyrosine Hydroxylase following Depolarization of Bovine Adrenal Chromaffin Cells. *Journal of Biological Chemistry* 269, 30960–30965 (1994).

181. Sutherland, C. et al. Phosphorylation and activation of human tyrosine hydroxylase in vitro by mitogen-activated protein (MAP) kinase and MAP-kinase-activated kinases 1 and 2. *European Journal of Biochemistry* 217, 715–722 (1993).
182. Moy, L. Y. & Tsai, L. H. Cyclin-dependent Kinase 5 phosphorylates serine 31 of tyrosine hydroxylase and regulates its stability. *Journal of Biological Chemistry* 279, 54487–54493 (2004).
183. Jorge-Finnigan, A. et al. Phosphorylation at serine 31 targets tyrosine hydroxylase to vesicles for transport along microtubules. *Journal of Biological Chemistry* 292, 14092–14107 (2017).
184. Daubner, S. C., Lauriano, C., Haycock, J. W. & Fitzpatrick, P. F. Site-directed mutagenesis of serine 40 of rat tyrosine hydroxylase. Effects of dopamine and cAMP-dependent phosphorylation on enzyme activity. *Journal of Biological Chemistry* 267, 12639–12646 (1992).
185. Haycock, J. et al. Role of serine-19 phosphorylation in regulating tyrosine hydroxylase studied with site- and phosphospecific antibodies and site-directed mutagenesis. *Journal of Neurochemistry* 71, 1670–1675 (1998).
186. Lindgren, N. et al. Regulation of tyrosine hydroxylase activity and phosphorylation at Ser(19) and Ser(40) via activation of glutamate NMDA receptors in rat striatum. *Journal of Neurochemistry* 74, 2470–2477 (2000).
187. Ghorbani, S., Szigetvari, P. D., Haavik, J. & Kleppe, R. Serine 19 phosphorylation and 14-3-3 binding regulate phosphorylation and dephosphorylation of tyrosine hydroxylase on serine 31 and serine 40. *Journal of Neurochemistry* 152, 29–47 (2020).
188. Obsilova, V. et al. The 14-3-3 protein affects the conformation of the regulatory domain of human tyrosine hydroxylase. *Biochemistry* 47, 1768–1777 (2008).
189. Toska, K. et al. Regulation of tyrosine hydroxylase by stress-activated protein kinases. *Journal of Neurochemistry* 83, 775–783 (2002).
190. Kleppe, R., Toska, K. & Haavik, J. Interaction of phosphorylated tyrosine hydroxylase with 14-3-3 proteins: Evidence for a phosphoserine 40-dependent association. *Journal of Neurochemistry* 77, 1097–1107 (2001).
191. Funakoshi, H. et al. Different effects on activity caused by phosphorylation of tyrosine hydroxylase at serine 40 by three multifunctional protein kinases. *Journal of Biological Chemistry* 266, 15614–15620 (1991).
192. Gonçalves, C.-A. et al. Tyrosine Hydroxylase Phosphorylation in Digitonin-Permeabilized Bovine Adrenal Chromaffin Cells: The Effect of Protein Kinase and Phosphatase Inhibitors on Ser19 and Ser40 Phosphorylation. *Journal of Neurochemistry* 69, 2387–2396 (1997).
193. Fitzpatrick, P. F. Tetrahydropterin-Dependent Amino Acid Hydroxylases. *Annual Review of Biochemistry* 68, 355–381 (1999).
194. Zigmond, R. E., Schwarzschild, M. A. & Rittenhouse, A. R. Acute regulation of tyrosine hydroxylase by nerve activity and by neurotransmitters via phosphorylation. *Annual Review of Neuroscience* 12, 415–461 (1989).
195. Meligeni JA, Haycock JW, Bennett WF, Waymire JC. Phosphorylation and activation of tyrosine hydroxylase mediate the cAMP-induced increase in catecholamine biosynthesis in adrenal chromaffin cells. *Journal of Biological Chemistry*, 257, 12632-12640 (1982).
196. Tachikawa, E. et al. Tyrosine Hydroxylase Is Activated and Phosphorylated on Different Sites in Rat Pheochromocytoma PC12 Cells Treated with Phorbol Ester and Forskolin. *Journal of Neurochemistry* 48, 1366–1376 (1987).

197. Waymire, J. & Johnston, J. Phosphorylation of bovine adrenal chromaffin cell tyrosine hydroxylase. Temporal correlation of acetylcholine's effect on site phosphorylation, enzyme activation, and catecholamine synthesis. *Journal of Biological Chemistry*, 263(25), 12439-12447 (1988).
198. Waymire, J. C. et al. Vasoactive Intestinal Peptide Stimulates Catecholamine Biosynthesis in Isolated Adrenal Chromaffin Cells: Evidence for a Cyclic AMP-Dependent Phosphorylation and Activation of Tyrosine Hydroxylase. *Journal of Neurochemistry* 57, 1313–1324 (1991).
199. Haycock, J. W. Four Forms of Tyrosine Hydroxylase Are Present in Human Adrenal Medulla. *Journal of Neurochemistry* 56, 2139–2142 (1991).
200. Bowyer, J. F. et al. Phosphorylation and activation of tyrosine hydroxylase in PC18 cells: a cell line derived from rat pheochromocytoma PC12 cells. *Brain Research* 591, 261–270 (1992).
201. Bobrovskaya, L., Cheah, T. B., Bunn, S. J. & Dunkley, P. R. Tyrosine hydroxylase in bovine adrenal chromaffin cells: Angiotensin II- stimulated activity and phosphorylation of Ser19 Ser31 and Ser40. *Journal of Neurochemistry* 70, 2565–2573 (1998).
202. Goldstein, M. et al. Antibodies to a Segment of Tyrosine Hydroxylase Phosphorylated at Serine 40. *Journal of Neurochemistry* 64, 2281–2287 (1995).
203. Waymire, J. C., Ayling, J. E. & Craviso, G. L. Nicotinic cholinergic regulation of tetrahydrobiopterin levels in bovine adrenal chromaffin cells. *Advances in Experimental Medicine and Biology* 338, 235–238 (1993).
204. Haycock, J. W. Short- and Long-Term Regulation of Tyrosine Hydroxylase in Chromaffin Cells by VIP and PACAPa. *Annals of the New York Academy of Sciences* 805, 219–230 (1996).
205. Raghuraman, G., Rai, V., Peng, Y. J., Prabhakar, N. R. & Kumar, G. K. Pattern-specific sustained activation of tyrosine hydroxylase by intermittent hypoxia: Role of reactive oxygen species-dependent downregulation of protein phosphatase 2a and upregulation of protein kinases. *Antioxidants and Redox Signaling* 11, 1777–1789 (2009).
206. Haycock, J. W. Multiple signaling pathways in bovine chromaffin cells regulate tyrosine hydroxylase phosphorylation at Ser19, Ser31, and Ser40. *Neurochemical Research* 18, 15–26 (1993).
207. Bobrovskaya, L. et al. Sustained phosphorylation of tyrosine hydroxylase at serine 40: A novel mechanism for maintenance of catecholamine synthesis. *Journal of Neurochemistry* 100, 479–489 (2007).
208. Zhang, D., Kanthasamy, A., Anantharam, V. & Kanthasamy, A. Effects of manganese on tyrosine hydroxylase (TH) activity and TH-phosphorylation in a dopaminergic neural cell line. *Toxicology and Applied Pharmacology* 254, 65–71 (2011).
209. Ahn, J.-H., Kim, Y., Kim, H.-S., Greengard, P. & Nairn, A. C. Protein Kinase C-Dependent Dephosphorylation of Tyrosine Hydroxylase Requires the B56 δ Heterotrimeric Form of Protein Phosphatase 2A. *PLoS ONE* 6, e26292 (2011).
210. Alterio, J. et al. Human tyrosine hydroxylase isoforms: Inhibition by excess tetrahydropterin and unusual behavior of isoform 3 after cAMP-dependent protein kinase phosphorylation. *Journal of Biological Chemistry* 273, 10196–10201 (1998).
211. Hofmann, F., Ammendola, A. & Schlossmann, J. Rising behind NO: cGMP-dependent protein kinases. *Journal of Cell Science* 113, 1671–1676 (2000).
212. Rodríguez-Pascual, F., Ferrero, R., Miras-Portugal, M. T. & Torres, M. Phosphorylation of tyrosine hydroxylase by cGMP-dependent protein kinase in intact bovine chromaffin cells. *Archives of Biochemistry and Biophysics* 366, 207–214 (1999).

213. Roskoski, R. & Roskoski, L. M. Activation of Tyrosine Hydroxylase in PC12 Cells by the Cyclic GMP and Cyclic AMP Second Messenger Systems. *Journal of Neurochemistry* 48, 236–242 (1987).
214. Roskoski, R., Vulliet, P. R. & Glass, D. B. Phosphorylation of Tyrosine Hydroxylase by Cyclic GMP-Dependent Protein Kinase. *Journal of Neurochemistry* 48, 840–845 (1987).
215. Haycock, J. W., Ahn, N. G., Cobb, M. H. & Krebs, E. G. ERK1 and ERK2, two microtubule-associated protein 2 kinases, mediate the phosphorylation of tyrosine hydroxylase at serine-31 in situ. *Proceedings of the National Academy of Sciences* 89, 2365–2369 (1992).
216. Núñez, C., Laorden, M. L. & Milanés, M. V. Regulation of serine (Ser)-31 and Ser40 tyrosine hydroxylase phosphorylation during morphine withdrawal in the hypothalamic paraventricular nucleus and nucleus tractus solitarius-A2 cell group: Role of ERK1/2. *Endocrinology* 148, 5780–5793 (2007).
217. Kansy, J. W. et al. Identification of tyrosine hydroxylase as a physiological substrate for Cdk5. *Journal of Neurochemistry* 91, 374–384 (2004).
218. Zhong, P. et al. Cyclin-dependent kinase 5 in the ventral tegmental area regulates depression-related behaviors. *Journal of Neuroscience* 34, 6352–6366 (2014).
219. Zhang, H. et al. Stimulatory effect of nobiletin, a citrus polymethoxy flavone, on catecholamine synthesis through Ser19 and Ser40 phosphorylation of tyrosine hydroxylase in cultured bovine adrenal medullary cells. *Naunyn-Schmiedeberg's Archives of Pharmacology* 387, 15–22 (2014).
220. Itagaki, C. et al. Stimulus-coupled interaction of tyrosine hydroxylase with 14-3-3 proteins. *Biochemistry* 38, 15673–15680 (1999).
221. Gordon, S. L. et al. The low affinity dopamine binding site on tyrosine hydroxylase: The role of the N-terminus and in situ regulation of enzyme activity. *Neurochemical Research* 34, 1830–1837 (2009).
222. Lehmann, I. T., Bobrovskaya, L., Gordon, S. L., Dunkley, P. R. & Dickson, P. W. Differential regulation of the human tyrosine hydroxylase isoforms via hierarchical phosphorylation. *Journal of Biological Chemistry* 281, 17644–17651 (2006).
223. Bevilacqua, Lia RM, et al. Phosphorylation of Ser19 Alters the Conformation of Tyrosine Hydroxylase to Increase the Rate of Phosphorylation of Ser40. *Journal of Biological Chemistry* 276, 40411–40416 (2001).
224. Bobrovskaya, L., Gelain, D. P., Gilligan, C., Dickson, P. W. & Dunkley, P. R. PACAP stimulates the sustained phosphorylation of tyrosine hydroxylase at serine 40. *Cellular Signalling* 19, 1141–1149 (2007).
225. Bobrovskaya, L., Dunkley, P. R. & Dickson, P. W. Phosphorylation of Ser19 increases both Ser40 phosphorylation and enzyme activity of tyrosine hydroxylase in intact cells. *Journal of Neurochemistry* 90, 857–864 (2004).
226. Zhang, G., Liu, Y., Ruoho, A. E. & Hurley, J. H. Structure of the adenylyl cyclase catalytic core. *Nature* 386, 247–253 (1997).
227. Taylor, S. S. et al. PKA: A portrait of protein kinase dynamics. *Biochimica et Biophysica Acta - Proteins and Proteomics* 1697, 259–269 (2004).
228. Taylor, S. S. et al. Dynamics of signaling by PKA. *Biochimica et Biophysica Acta - Proteins and Proteomics* 1754, 25–37 (2005).
229. Cheng, X., Ji, Z., Tsalkova, T. & Mei, F. Epac and PKA: A tale of two intracellular cAMP receptors. *Acta Biochimica et Biophysica Sinica* 40, 651–662 (2008).

230. Mons, N. et al. Immunohistochemical localization of adenylyl cyclase in rat brain indicates a highly selective concentration at synapses.
Proceedings of the National Academy of Sciences 92, 8473–8477 (1995).
231. Mons, N., Yoshimura, M. & Cooper, D. M. F. Discrete expression of Ca²⁺/calmodulin-sensitive and Ca²⁺-insensitive adenylyl cyclases in the rat brain.
Synapse 14, 51–59 (1993).
232. Furuyama, T., Inagaki, S. & Takagi, H. Distribution of type II adenylyl cyclase mRNA in the rat brain.
Molecular Brain Research 19, 165–170 (1993).
233. Matsuoka, I. et al. Localization of adenylyl and guanylyl cyclase in rat brain by in situ hybridization: comparison with calmodulin mRNA distribution.
The Journal of Neuroscience 12, 3350–3360 (1992).
234. Defer, N., Best-Belpomme, M. & Hanoune, J. Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase.
American Journal of Physiology - Renal Physiology 279, F400–F416 (2000).
235. Kaupp, U. B. & Seifert, R. Cyclic Nucleotide-Gated Ion Channels.
Physiological Reviews 82, 769–824 (2002).
236. Bos, J. L. Epac proteins: multi-purpose cAMP targets.
Trends in Biochemical Sciences 31, 680–686 (2006).
237. Wettschureck, N. & Offermanns, S. Mammalian G proteins and their cell type specific functions.
Physiological Reviews 85, 1159–1204 (2005).
238. Martemyanov, K. A. Mechanisms of G $\beta\gamma$ Release upon GPCR Activation.
Trends in Biochemical Sciences 46, 703–704 (2021).
239. Rasmussen, S. G. F. et al. Crystal structure of the β 2 adrenergic receptor-Gs protein complex.
Nature 477, 549–557 (2011).
240. Hanoune, J. & Defer, N. Regulation and Role of Adenylyl Cyclase Isoforms.
Annual review of pharmacology and toxicology, 41, 145–174 (2001).
241. Sunahara, R. K., Dessauer, C. W. & Gilman, A. G. Complexity and diversity of mammalian adenylyl cyclases.
Annual Review of Pharmacology and Toxicology 36, 461–480 (1996).
242. Gilman, A. G. G proteins and dual control of adenylyl cyclase.
Cell 36, 577–579 (1984).
243. Lindgren, N. et al. Dopamine D2 receptors regulate tyrosine hydroxylase activity and phosphorylation at Ser40 in rat striatum.
European Journal of Neuroscience 13, 773–780 (2001).
244. Ford, C. P. The role of D2-autoreceptors in regulating dopamine neuron activity and transmission.
Neuroscience 282, 13–22 (2014).
245. Butini, S. et al. Polypharmacology of dopamine receptor ligands.
Progress in Neurobiology 142, 68–103 (2016).
246. Harmor, A. J. Family-B G-protein-coupled receptors.
Genome Biology 2, 1–10 (2001).
247. Cauvin, A. et al. Rat PHI, PHI-GLY and PHV(1-42) stimulate adenylyl cyclase in six rat tissue and cell membranes.
Peptides (N.Y.) 11, 1009–1014 (1990).
248. Schwarzschild, M. A. et al. Activation of ganglionic tyrosine hydroxylase by peptides of the secretin-glucagon family: Structure-function studies.
Neuroscience 31, 159–167 (1989).
249. Hoosein, N. M. & Gurd, R. S. Human glucagon-like peptides 1 and 2 activate rat brain adenylyl cyclase.
FEBS Letters 178, 83–86 (1984).

250. Vaudry, D. et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: From structure to functions. *Pharmacological Reviews* 52, 269–324 (2000).
251. Harmar, A. J. et al. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR Review 1. *British Journal of Pharmacology* 166, 4–17 (2012).
252. Hashimoto, H., Ishihara, T., Shigemoto, R., Mori, K. & Nagata, S. Molecular cloning and tissue distribution of a receptor for pituitary adenylate cyclase-activating polypeptide. *Neuron* 11, 333–342 (1993).
253. Masuo, Y., Ohtaki, T., Masuda, Y., Tsuda, M. & Fujino, M. Binding sites for pituitary adenylate cyclase activating polypeptide (PACAP): comparison with vasoactive intestinal polypeptide (VIP) binding site localization in rat brain sections. *Brain Research* 575, 113–123 (1992).
254. Watanabe, T., Shimamoto, N., Takahashi, A. & Fujino, M. PACAP stimulates catecholamine release from adrenal medulla: A novel noncholinergic secretagogue. *American Journal of Physiology - Endocrinology and Metabolism* 269, (1995).
255. Marley, P. D., Cheung, C. Y., Thomson, K. A. & Murphy, R. Activation of tyrosine hydroxylase by pituitary adenylate cyclase-activating polypeptide (PACAP-27) in bovine adrenal chromaffin cells. *Journal of the Autonomic Nervous System* 60, 141–146 (1996).
256. Muller, A. et al. Pituitary adenylate cyclase-activating polypeptide triggers dual transduction signaling in CATH.a cells and transcriptionally activates tyrosine hydroxylase and c-fos expression. *Journal of Neurochemistry* 68, 1696–1704 (1997).
257. Ip NY, Baldwin C, Zigmond RE. Regulation of the concentration of adenosine 3',5'-cyclic monophosphate and the activity of tyrosine hydroxylase in the rat superior cervical ganglion by three neuropeptides of the secretin family. *Journal of Neuroscience* 5, 1947–1954 (1985).
258. Roskoski, R., White, L., Knowlton, R. & Roskoski, L. M. Regulation of tyrosine hydroxylase activity in rat PC12 cells by neuropeptides of the secretin family. *Molecular Pharmacology* 36, 925–931 (1989).
259. Wessels-Reiker M, Basiboina R, Howlett AC, Strong R. Vasoactive Intestinal Polypeptide-Related Peptides Modulate Tyrosine Hydroxylase Gene Expression in PC12 Cells Through Multiple Adenylate Cyclase-Coupled Receptors. *Journal of Neurochemistry* 60, 1018–1029 (1993).
260. Francis, S. H., Busch, J. L. & Corbin, J. D. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. *Pharmacological Reviews* 62, 525–563 (2010).
261. Potter, L. R., Abbey-Hosch, S. & Dickey, D. M. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. *Endocrine Reviews* 27, 47–72 (2006).
262. Potter, L. R. Guanylyl cyclase structure, function and regulation. *Cellular Signalling* 23, 1921–1926 (2011).
263. Lucas, K. A. et al. Guanylyl cyclases and signaling by cyclic GMP. *Pharmacological Reviews* 52, 375–413 (2000).
264. Wong, S. K. F. & Garbers, D. L. Receptor guanylyl cyclases. *Journal of Clinical Investigation* 90, 299–305 (1992).
265. Kuhn, M. Molecular physiology of membrane guanylyl cyclase receptors. *Physiological Reviews* 96, 751–804 (2016).

266. Hurley, J. H. The adenylyl and guanylyl cyclase superfamily. *Current Opinion in Structural Biology* 8, 770–777 (1998).
267. Beavo, J. A. & Brunton, L. L. Cyclic nucleotide research - Still expanding after half a century. *Nature Reviews Molecular Cell Biology* 3, 710–718 (2002).
268. Zaccolo, M. & Movsesian, M. A. cAMP and cGMP signaling cross-talk: Role of phosphodiesterases and implications for cardiac pathophysiology. *Circulation Research* 100, 1569–1578 (2007).
269. Yanagihara, N. et al. Stimulatory effects of brain natriuretic peptide on cyclic GMP accumulation and tyrosine hydroxylase activity in cultured bovine adrenal medullary cells. *Naunyn-Schmiedeberg's Archives of Pharmacology* 343, 289–295 (1991).
270. Tsutsui, M. et al. C-type natriuretic peptide stimulates catecholamine synthesis through the accumulation of cyclic GMP in cultured bovine adrenal medullary cells. *Journal of Pharmacology and Experimental Therapeutics* 268, 584–589 (1994).